Several Ebola Vaccines Are Being Tested Worldwide In Clinical Trials

 

Ebola Vaccines

The Ebola virus is one of the deadliest viruses known to man, with a mortality rate of up to 90%. It first appeared in 1976 in two simultaneous outbreaks, one in Sudan and the other in the Democratic Republic of Congo. Since then, there have been sporadic outbreaks, mostly in Africa, but the deadliest outbreak occurred between 2014 and 2016, with over 28,000 cases and over 11,000 deaths. The lack of an Ebola Vaccines for the Ebola virus made it difficult to contain the spread of the disease during these outbreaks. However, after years of research, scientists discovered an Ebola vaccine, which has been instrumental in containing the spread of the disease in recent years.

The search for the Ebola Vaccines began in earnest in the mid-1990s when several Ebola outbreaks occurred in Africa. At that time, researchers were able to identify the genetic makeup of the virus and began exploring ways to create a vaccine. However, progress was slow, and it was not until the outbreak in West Africa in 2014 that the search for a vaccine gained renewed urgency.

Several vaccines were in development, but one of the most promising was the rVSV-ZEBOV vaccine, which was developed by a team of researchers from the Public Health Agency of Canada and licensed to the pharmaceutical company Merck. The vaccine is a type of recombinant vesicular stomatitis virus (rVSV) that has been modified to contain a gene from the Ebola virus (ZEBOV).

The rVSV-ZEBOV Ebola Vaccines was first tested in a phase I clinical trial in 2015, which showed that it was safe and generated an immune response. The vaccine was then tested in a phase III trial in Guinea, which was one of the countries hardest hit by the Ebola outbreak. The trial involved over 11,000 participants and was conducted using a ring vaccination strategy, which involved vaccinating all close contacts of an infected person, as well as their contacts. The trial showed that the vaccine was highly effective, with a 100% efficacy rate at 10 days after vaccination.

 

Comments

Popular posts from this blog

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy

The Isocyanates Market to Witness Robust Growth in North America and Asia Pacific

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins